GO:0008612 peptidyl-hypusine biosynthetic process

The Gene Ontology term GO:0008612, peptidyl-hypusine biosynthetic process, defines the post-translational modification of a peptidyl-lysine residue to form hypusine, an unusual amino acid essential for the function of eukaryotic translation initiation factor 5A (eIF5A). This process is the only known example of hypusine synthesis in biology and is highly conserved from archaea to humans. Hypusine biosynthesis is critical for cell proliferation, differentiation, and survival, and its dysregulation has been implicated in various human diseases, including cancer and neurodegeneration. Researchers study this pathway to understand fundamental translation control and to develop targeted therapies. The enzymatic steps involve deoxyhypusine synthase (DHPS) and deoxyhypusine hydroxylase (DOHH), which sequentially modify a specific lysine in eIF5A. Because hypusine formation is essential for eIF5A activity, manipulating this pathway via CRISPR-based genome editing offers powerful strategies to investigate its roles in health and disease.

GO:0008612 describes the biochemical process in which a lysine residue within a protein (specifically eIF5A) is post-translationally modified to become hypusine, N6-(4-amino-2-hydroxybutyl)-lysine. This modification is unique and requires two enzymatic reactions: first, the transfer of a 4-aminobutyl group from spermidine to the lysine's epsilon-amino group by deoxyhypusine synthase, forming deoxyhypusine; second, hydroxylation of the deoxyhypusine intermediate by deoxyhypusine hydroxylase to yield mature hypusine. The process is essential for eIF5A function in translation elongation.

The peptidyl-hypusine biosynthetic process is vital because it is the sole route to activate eIF5A, a translation factor required for the synthesis of proteins containing consecutive proline residues and for general cell viability. Without hypusination, eIF5A remains inactive, leading to impaired translation elongation, cell cycle arrest, and apoptosis. This pathway has been linked to numerous physiological and pathological contexts, including embryonic development, immune responses, and cancer progression. Moreover, pathogens such as trypanosomes and Leishmania rely on hypusination for survival, making the enzymes DHPS and DOHH potential drug targets. Understanding GO:0008612 therefore provides insights into basic translation mechanisms and offers therapeutic opportunities for a range of diseases.

The following genes and proteins are central to the peptidyl-hypusine biosynthetic process and are frequently studied in research.

The peptidyl-hypusine biosynthetic process is regulated at multiple levels. mTORC1 signaling promotes hypusination by increasing DHPS expression and spermidine availability. Conversely, nutrient deprivation or mTOR inhibition reduces hypusination, linking the pathway to cellular energy status. Additionally, DHPS activity can be modulated by feedback inhibition and post-translational modifications. The availability of spermidine, controlled by polyamine biosynthesis enzymes (ODC1, SRM, SMS), directly impacts hypusination rates. Under stress conditions, such as hypoxia, HIF1A may regulate DHPS transcription. These regulatory mechanisms ensure that eIF5A activation is tightly coupled to cell growth and proliferation demands.

Hypusination is frequently upregulated in many cancers, including colorectal, breast, and pancreatic cancer, where it supports rapid cell proliferation and survival. DHPS and DOHH are overexpressed in some tumors, and inhibition of hypusination reduces tumor growth in preclinical models. eIF5A hypusination also contributes to cancer stem cell maintenance and metastasis. Targeting the hypusine pathway with small molecule inhibitors or CRISPR knockout is a promising therapeutic strategy.

Reduced hypusination has been observed in models of neurodegeneration, such as Alzheimer's and Parkinson's diseases, where impaired eIF5A function may contribute to neuronal death. eIF5A hypusination is important for neuronal survival and synaptic function. Modulating the pathway could offer neuroprotective benefits, although further research is needed.

Parasitic protozoa like Trypanosoma brucei and Leishmania species depend on hypusination for survival, and their DHPS enzymes are structurally distinct from human DHPS, making them attractive drug targets. Inhibitors of hypusination have shown antiparasitic activity. The pathway is also important in some viruses, where eIF5A hypusination is required for viral replication.

Mutations in DHPS or DOHH cause rare developmental disorders characterized by neurological impairment and growth retardation. These conditions highlight the essential role of hypusination in human development. Studying patient-derived cells with CRISPR correction can provide insights into disease mechanisms.

Hypusinated eIF5A can be detected using specific antibodies that recognize the hypusine modification. Western blotting allows quantification of hypusine levels relative to total eIF5A. This method is widely used to assess the effects of genetic or pharmacological perturbations on the pathway.

Mass spectrometry-based proteomics can identify and quantify hypusine modifications on eIF5A, providing precise stoichiometry and site-specific information. This approach is valuable for studying hypusination dynamics and identifying off-target effects of inhibitors.

CRISPR-Cas9 is used to generate knockout, point mutation, and knock-in models to dissect the function of DHPS, DOHH, and EIF5A. These models enable causal testing of hypusination in cellular processes and disease phenotypes.

Ribo-seq measures translation efficiency and ribosome stalling at proline-rich sequences, which is sensitive to eIF5A hypusination status. This technique can reveal the impact of hypusination on global translation and specific transcripts.

Researchers studying peptidyl-hypusine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in the pathway, and CRISPR-based genome editing provides the most direct approach. By generating knockout, point mutation, knock-in, and overexpression models, scientists can dissect the precise roles of DHPS, DOHH, EIF5A, and other regulators in hypusination and its downstream effects.

The peptidyl-hypusine biosynthetic process (GO:0008612) is a unique and essential post-translational modification that activates eIF5A, a key translation factor. Its dysregulation is implicated in cancer, neurodegeneration, and infectious diseases, making it a compelling target for therapeutic intervention. Advances in CRISPR genome editing and other molecular tools continue to unravel the complexities of this pathway, offering new opportunities for drug discovery and disease modeling. EDITGENE's comprehensive CRISPR services support researchers in dissecting the roles of DHPS, DOHH, EIF5A, and other components of this critical pathway.